Iomazenil

Iomazenil is a benzodiazepine antagonist used in the treatment of benzodiazepine overdoses. It is marketed under the brand name Anexate but only in certain countries. Iomazenil is not approved for marketing in the United States, but it has been studied clinically.

Etymology

The name "Iomazenil" is derived from its chemical structure, which is a benzodiazepine derivative. The "Io" prefix is derived from the Greek word "ion", meaning "going", which refers to its ability to reverse the effects of benzodiazepines. The "mazenil" suffix is common to other benzodiazepine antagonists, such as flumazenil.

Pharmacology

Iomazenil, like other benzodiazepine antagonists, works by binding to the benzodiazepine site on the GABA_A receptor and preventing the action of benzodiazepines and related drugs. It has a high affinity for the benzodiazepine receptor, but it does not have any intrinsic activity, so it does not produce any effects on its own. Instead, it blocks the effects of other drugs that act on the benzodiazepine receptor.

Clinical use

Iomazenil is used in the treatment of benzodiazepine overdoses. It can reverse the sedation and respiratory depression that are often seen in these cases. However, it does not reverse other effects of benzodiazepines, such as amnesia or muscle relaxation.

Side effects

The most common side effects of iomazenil are dizziness, headache, and nausea. These are usually mild and transient. More serious side effects can occur, including seizures, especially in patients with a history of epilepsy or other seizure disorders.

See also

• Benzodiazepine
• Benzodiazepine antagonist
• GABA_A receptor
• Flumazenil

Iomazenil Resources
Latest articles Most recent articles Ongoing trials	Wikipedia